Cargando…
Tissue plasminogen activator for axillary Impella 5.0 with heparin-induced thrombocytopenia as a treatment of choice for acute Impella thrombosis: a case report
BACKGROUND: Patients with cardiogenic shock requiring temporary support with percutaneous ventricular assist device, such as Impella (Abiomed, Inc.), can develop heparin-induced thrombocytopenia (HIT) which requires use of alternative purge solution anticoagulation. There are limited recommendations...
Autores principales: | Merino, Elena, Abdelfattah, Omar M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180370/ https://www.ncbi.nlm.nih.gov/pubmed/37187969 http://dx.doi.org/10.1093/ehjcr/ytad231 |
Ejemplares similares
-
The role of the axillary Impella 5.0 device on patients with acute cardiogenic shock
por: Tarabichi, Saeed, et al.
Publicado: (2020) -
Hemodynamic Support Using Percutaneous Transfemoral Impella 5.0 and Impella RP for Refractory Cardiogenic Shock
por: Dalal, Pratik K., et al.
Publicado: (2019) -
Impella flow pump reinsertion after axillary graft thrombectomy: Technical points in replacing axillary Impella
por: Haddad, Osama, et al.
Publicado: (2021) -
Impella 5.0 supported oncological surgery as bridge to LVAD
por: Montisci, Andrea, et al.
Publicado: (2020) -
Severe Left Ventricular Failure Unmanageable by Impella 5.0
por: Mano, Akiko, et al.
Publicado: (2023)